Statement: There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 3/8 (37.50%)   Anaemia 0/8 (0.00%)   Febrile neutropenia 0/8 (0.00%)   Polycythaemia 0/8 (0.00%)   Acute coronary syndrome 0/8 (0.00%)   Vertigo 0/8 (0.00%)   Eyelid oedema 1/8 (12.50%)   Constipation 0/8 (0.00%)   Diarrhoea 0/8 (0.00%)   Nausea 0/8 (0.00%)   Stomatitis 0/8 (0.00%)   Upper gastrointestinal haemorrhage 0/8 (0.00%)   Vomiting 0/8 (0.00%)   Chest pain 0/8 (0.00%) Adverse Events 2:   Total: 2/6 (33.33%)   Anaemia 0/6 (0.00%)   Febrile neutropenia 0/6 (0.00%)   Polycythaemia 0/6 (0.00%)   Acute coronary syndrome 0/6 (0.00%)   Vertigo 0/6 (0.00%)   Eyelid oedema 0/6 (0.00%)   Constipation 0/6 (0.00%)   Diarrhoea 0/6 (0.00%)   Nausea 0/6 (0.00%)   Stomatitis 0/6 (0.00%)   Upper gastrointestinal haemorrhage 0/6 (0.00%)   Vomiting 0/6 (0.00%)   Chest pain 1/6 (16.67%)